Thomas J. Tarlow

Vice President-Regulatory Affairs & Quality at Talon Therapeutics, Inc.

Thomas J. Tarlow

Thomas J. Tarlow

Vice President-Regulatory Affairs & Quality at Talon Therapeutics, Inc.

Biography

Thomas J. Tarlow joined Talon as Vice President on January 7, 2009. Prior to assuming his current responsibilities, Mr. Tarlow served as Vice President, Regulatory Affairs at Tercica, Inc. from October 2006 to December 2008. Prior to that appointment, Mr. Tarlow held various senior positions in regulatory affairs at Amgen, SUGEN, and ALZA. Mr. Tarlow received his MS in Comparative Pathology from the University of California, Davis, School of Veterinary Medicine and his BA in Biology from the University of California, Santa Cruz.

Overview
RelSci Relationships

58

Birthday

1950

Age

68

Relationships
RelSci Relationships are individuals Thomas J. Tarlow likely has professional access to. A relationship does not necessarily indicate a personal connection.

Controller & Director of Finance at Talon Therapeutics, Inc.

Relationship likelihood: Strong

Executive Vice President, Chief Accounting Officer & Chief Financial Officer at Spectrum Pharmaceuticals, Inc.

Relationship likelihood: Strong

Former Vice President, Finance & Chief Financial Officer at Neurobiological Technologies, Inc.

Relationship likelihood: Average

Former Vice President, Controller at Talon Therapeutics, Inc.

Relationship likelihood: Average

Former Chief Financial Officer, Secretary & Vice President at Talon Therapeutics, Inc.

Relationship likelihood: Average

President, Chief Executive Officer & Director at Medeor Therapeutics, Inc.

Relationship likelihood: Average

President at GMF Capital LLC

Relationship likelihood: Average

Former Executive Director-Bay Area Operations at ALZA Corp.

Relationship likelihood: Average

Owner at Assist-2-Sell, Inc.

Relationship likelihood: Average

Founder at Centre for Non-Profit Leadership

Relationship likelihood: Average

Paths to Thomas J. Tarlow
Potential Connections via
Relationship Science
You
Thomas J. Tarlow
Vice President-Regulatory Affairs & Quality at Talon Therapeutics, Inc.
Education

The University of California, Davis (also referred to as UCD, UC Davis, or Davis) is a public teaching and research university located in Davis, California just west of Sacramento. The campus covers 7,309 acres (2,958 ha), making it the largest within the 10 campus University of California system. UC Davis also has the third largest enrollment in the UC System after UCLA and UC Berkeley. The University of California, Davis campus is the largest campus in the UC system by land area, spanning 7,309 acres (2,957.8 ha) across two counties: Yolo and Solano. Though named after the City of Davis, the campus is technically located adjacent to the City of Davis in an unincorporated part of Yolo and Solano counties. The main campus is located 15 miles (24.1 km) west of Sacramento in the Sacramento Valley, part of California's Central Valley, and is adjacent to Interstate Highway 80. The Davis campus is the only school within the UC system with an airport, just west of main campus, and is one of two UC schools with its own fire department; the other being UC Santa Cruz. The campus is also conveniently located approximately an hour away from both San Francisco and the Napa Valley and two hours from Lake Tahoe. It is also one of only three schools in the University of California system, the others being UC Berkeley and UC Irvine, with a nuclear lab.

The University of California, Santa Cruz, has earned international distinction as a university with high-impact research and an uncommon commitment to teaching and public service. A campus with world-class facilities and one of the most visually spectacular settings in higher education, UC Santa Cruz provides unparalleled opportunities for students to learn through hands-on experience. A commitment to environmental stewardship and community engagement are also central to UCSC's core values.

Career History
Vice President-Regulatory Affairs & Quality
2009 - Current

Talon Therapeutics, Inc. is a biopharmaceutical company, which is engaged in the developing and commercializing new and differentiated cancer therapies. The firm is developing the Marqibo for the treatment of acute lymphoblastic leukemia and other blood cancers including lymphoma. Its Menadione topical lotion is a compound which is developed for the prevention and treatment of skin toxicity associated with epidermal growth factor receptor inhibitors. The company was founded by Mark J. Ahn in 2002 and is headquartered in San Mateo, CA.

Vice President-Regulatory Affairs & Document Archives
Prior

The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc.

Political Donations
$1,300
2008

Former President of United States

Other Affiliations

Thomas J. Tarlow is affiliated with Talon Therapeutics, Inc., Tercica, Inc.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Thomas J. Tarlow. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Thomas J. Tarlow's profile does not indicate a business or promotional relationship of any kind between RelSci and Thomas J. Tarlow.